Chief executive Craig Gulliford said the milestone reflects growing clinician engagement and real-world momentum as physicians gain experience with the device.
The surgical device maker raised its full-year revenue growth forecast to 50-60% after first-quarter sales came in at the top of management's expectations.
A partial buyout sees a 49% holding in Creo Medical being acquired by the unit's CEO, on terms that set an indicative enterprise value in line with its carrying value.
Tech and medicine development major aims to raise new capital to support investments in its Bipolar product range ahead of a 2027 commercial launch.
SpydrBlade™ Flex was used to perform two BEAM bariatric endoscopic antral myotomy procedures, and the cases were presented at Frontiers in Endoscopic Surgery 2026.
Creo Medical Group recorded around 60% year‑on‑year revenue growth in Q1 FY26 and says that performance keeps it on track to deliver 40%–60% full‑year revenue growth for 2026.